MARKET

MRSN

MRSN

Mersana Therapeutics Inc
NASDAQ
29.10
+0.04
+0.14%
Closed 16:10 12/18 EST
OPEN
29.03
PREV CLOSE
29.06
HIGH
29.10
LOW
28.72
VOLUME
38.47K
TURNOVER
--
52 WEEK HIGH
56.00
52 WEEK LOW
5.21
MARKET CAP
145.46M
P/E (TTM)
-2.0661
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MRSN last week (1208-1212)?
Weekly Report · 4d ago
Serina Therapeutics Appoints Dr. Joshua Thomas as Vice President and Head of Chemistry
Reuters · 12/11 21:15
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
Seeking Alpha · 12/10 15:26
Weekly Report: what happened at MRSN last week (1201-1205)?
Weekly Report · 12/08 10:19
Weekly Report: what happened at MRSN last week (1124-1128)?
Weekly Report · 12/01 10:15
Weekly Report: what happened at MRSN last week (1117-1121)?
Weekly Report · 11/24 10:20
Weekly Report: what happened at MRSN last week (1110-1114)?
Weekly Report · 11/17 10:20
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
Barchart · 11/16 18:04
More
About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Webull offers Mersana Therapeutics Inc stock information, including NASDAQ: MRSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRSN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRSN stock methods without spending real money on the virtual paper trading platform.